Ask AI
ProCE Banner Activity

CELMoDs in Multiple Myeloma

Clinical Thought

In this commentary derived from a recent symposium, experts discuss CELMoD therapy for multiple myeloma, including the mechanism of action, available clinical data, ongoing trials, and future implications.

Released: July 28, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb

Faculty Disclosure

Primary Author

Jesus Berdeja, MD: researcher (paid to institution): AstraZeneca, Bristol Myers Squibb, C4 Therapeutics, Caribou Biosciences, CARsgen, Cartesian, Genentech, GlaxoSmithKline, Gracell, Ichnos Sciences, Johnson & Johnson, Juno, K36 Therapeutics, Karyopharm, Kite, Moderna, Pfizer, Regeneron, Roche, Sanofi; consultant: AstraZeneca, Bristol Myers Squibb, Galapagos, Johnson & Johnson, Kite, Kyowa Kirin, Pfizer, Regeneron, Roche, Sebia; speaker: Janssen.

Amrita Krishnan, MD, FACP: consultant/advisor/speaker: AstraZeneca, Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche, Sanofi; individual publicly traded stock/stock options: Arcellx, Bristol Myers Squibb.

Sagar Lonial, MD, FACP: consultant/advisor/speaker: AbbVie, Amgen, Bristol Myers Squibb, Genentech, GlaxoSmithKline, Janssen, Novartis, Pfizer, Regeneron, Takeda; researcher: Bristol Myers Squibb, Janssen, Novartis, Takeda; other financial or material support: TG Therapeutics.